NKGen Biotech extends Meteora FPA valuation to Dec 2026, adds $372k AlpineBrook debt

On January 20, 2026, NKGen Biotech, Inc. (the “Company” and formerly known as Graf Acquisition Corp. IV) and Seller (defined below) entered into an eighth amendment (the “FPA Amendment”) to the forward purchase agreement, dated as of September 22, 2023 (the “FPA”), initially among the Company, Graf, Meteora Strategic Capital, LLC (“MSC”), Meteora Capital Partners, LP (“MCP”) and Meteora Select Trading Opportunities Master, LP (“MSTO” with MSC, MCP, and MSTO collectively, “Seller”) for OTC Equity Prepaid Forward Transactions, as amended on December 26, 2023, as further amended on January 2, 2024, January 11, 2024, February 21, 2024, July 12, 2024, September 5, 2024, and December 31, 2024.

On January 23, 2026, the Company and NKGen Operating Biotech, Inc., a Delaware corporation (together with the Company, the “Borrowers”), entered into a second amendment (the “Alpine Second Amendment”) to that certain secured promissory note with AlpineBrook Capital GP I Limited, dated January 5, 2026, as amended by that certain amendment to secured promissory note dated January 12, 2026 (the “Note”). The Alpine Second Amendment provides an additional $372,000 of funding to the Borrowers (the “Third Additional New Loan”). As a result, the principal amount of the Note was increased to $26,507,106.